Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264798 | 0.81 | CA12 (0.45) | SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL13016814 | 0.75 | CACNA2D1 (0.40) | CPA1 | |
| SCHEMBL3262445 | 0.72 | CPA1 (0.35) | CPA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17865359 | 0.70 | SLC1A3 (0.55) | SLC1A3SLC1A1 | |
| SCHEMBL6478425 | 0.68 | CYP2C9 (0.33) | MEN1KMT2A | |
| SCHEMBL4007890 | 0.65 | SLC1A2 (0.49) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13397168 | 0.65 | ALDH1A1 (0.34) | MEN1KMT2A | |
| SCHEMBL7268957 | 0.64 | HSD17B10 (0.43) | CPA1SLC1A3SLC1A2MEN1GAA | |
| SCHEMBL9115232 | 0.64 | SLC1A3 (0.64) | CPA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL978770 | 0.63 | TSHR (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101830824-A | The medicine of treatment chronic pain | NICOX SA | 2010-09-15 | — | — | CN | claimed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | claimed |
| CN-1729160-A | Medicine for treating chronic pain | NICOX SA (FR) | 2006-02-01 | — | — | CN | claimed |
| CN-1729160-B | Medicine for treating chronic pain | NICOX SA | 2011-08-03 | — | — | CN | disclosed |
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| CN-101830824-A | The medicine of treatment chronic pain | NICOX SA | 2010-09-15 | — | — | CN | disclosed |
| US-7642289-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| CN-1729160-A | Medicine for treating chronic pain | NICOX SA (FR) | 2006-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | CPA1 4057/4885SLC1A3 402/4885SLC1A2 200/4885 |
| US-20060270608-A1 | Drugs for chronic pain | OPRK1, OPRL1, OPRD1 | CPA1 4057/4885SLC1A3 402/4885SLC1A2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.